Details of our 2020 Scientific Conference will be available here soon. In the meantime watch the overview video of our 2019 Conference in Rome.
The International Aspirin Foundation Scientific Conference in 2015 attracts prestigious speakers from all over the world.
Bleeding attributable to aspirin: I continue to monitor the literature for evidence on bleeding attributable to aspirin and I become ever more convinced that the risk and the seriousness of a bleed is grossly exaggerated. I have had papers on this refused, but one editorial has been published (Gastroenterology and Hepatology 2014;10:1-3).
Colorectal Cancer Screening and a role for aspirin: I believe that it is for colon cancer that aspirin will first become accepted by our clinical colleagues and by policy makers. I further believe that aspirin alongside colorectal screening is highly attractive ethically and economically.
Last year we published a paper with the above title. I am now doing what I can to stimulate the interest of colleagues locally and I have written a letter summarising the risks, benefits and ethical issues to the chair of the UK National Screening Committee.
Aspirin and cancer: I am active locally in doing what I can to get clinicians, and a very large charity in Wales, to recognise the likely value of aspirin used as an adjunct treatment of cancer. The discussions I have had so far focus on prostate and colon cancer.
A web site on aspirin prophylaxis. We already have a video on YouTube (http://youtu.be/yVCs0wxp_Vc). We are now working on a web site.
Natural Salicylates: We are doing a pre-pilot study of salicylates in urine samples stored for many years. If salicylates can be detected we hope this may open up a way to test the prediction of cancer by fruit and veg consumption.
I am a chronic disease epidemiologist. I have a particular interest in the roles that individual lifestyle choices (diet, exercise, smoking), metabolic factors (obesity, high cholesterol, and hypertension), and biochemical and genetic markers play on the risk of coronary artery disease and stroke. Also of interest is the impact that vascular disease has on other organ systems, including cognitive dysfunction and renal disease.
Recently, I have initiated a number of research projects to investigate the diverse nature of atherosclerosis and I serve as the director of the Geriatric Research and Education Center (GRECC) at the VA Boston Healthcare System.
Dr. Andrew T. Chan is an Associate Professor of Medicine at Harvard Medical School and an attending gastroenterologist at Massachusetts General Hospital (MGH) with a clinical specialty in familial gastrointestinal cancer syndromes. He is Chief of the Clinical and Translational Epidemiology Unit and the Program Director for gastroenterology training at MGH. His research focus is in clinical and translational epidemiology of colorectal cancer, with a focus on chemoprevention with aspirin.
Joan Clària is currently a Senior Consultant at the Clinical Laboratory Service: Biochemistry and Molecular Genetics of the Hospital Clínic of Barcelona. He is also an Associate Professor at the Department of Physiological Sciences I at the School of Medicine of the University of Barcelona. He was trained as a specialist in Clinical Biochemistry and initiated his scientific career at the Liver Unit of the Hospital Clínic of Barcelona. From 1993 to 1996 he performed his post-doctoral studies as a Fulbright scholar at the Brigham and Women’s Hospital and Harvard Medical School (Boston, MA) with Professor Charles N. Serhan, a leading scientist in the resolution of inflammation. He has also been a Visiting Scientist at the University of North Carolina (Chapel Hill, NC) (2001) and The Jackson Laboratory (Bar Harbor, ME) (2007) and a Visiting Professor at the Harvard Institutes of Medicine (Brigham and Women’s Hospital/Harvard Medical School) (Boston, MA) (2010-2011). His laboratory is mainly interested in the study of lipid mediators implicated in the resolution of inflammation, with a special emphasis on the role of specialized pro-resolving mediators in obesity-associated liver complications.
Reader and Honorary Consultant in Infectious Diseases at Cardiff University and University Hospital of Wales. He qualified in Medicine from Cambridge University & St Thomas’ Hospital in 1980, and subsequently trained in Infectious Diseases at St George’s Hospital, London and Harvard Medical School, USA, before coming to Cardiff in 1994. His research interests include the effects of HIV on bone marrow and thymic function. He is a trustee of the British HIV Association and chair of its Audit & Standards sub-committee, and a previous member of the DH Expert Advisory Group on AIDS
Professor Graham Hughes trained at The London Hospital. In 1969-70, he spent 2 years with Professor Charles Christian in New York working on the introduction of anti-DNA assays in lupus.
In 1971 he set up Europe’s first dedicated lupus clinic.
In 1983 he described the antiphospholipid syndrome (Hughes Syndrome).
Professor Hughes has published widely on lupus and connective tissue diseases, and has published 21 books. He is Founder and Editor of the international journal ‘LUPUS’, now in its 23rd year.
His honours include the ILAR International Prize for Rheumatology Research,
and Docteur Honoris Causa in the Universities of Marseille and Barcelona.
Professor Hughes is currently Head of The London Lupus Centre, London Bridge Hospital (www.thelondonlupuscentre.com)
Angel Lanas is Professor of Medicine of the University of Zaragoza, Vice-Dean for Research Affairs at the Medical School of Medicine University of Zaragoza, Chairman of the Digestive Diseases Service at the University Hospital “Lozano Blesa” of Zaragoza, Spain and Scientific Director of the Aragón Health Research Institute.
Professor Angel Lanas received his medical degree from the University of Zaragoza, Spain in 1984 and did his postgraduate training in internal medicine-gastroenterology at the University Hospital at Zaragoza and was visiting professor to the Department of Gastroenterology at the University of Alabama in Birmingham, Alabama, USA since November 1989 to December 1991, where he worked with Professor Basil Hirschowitz. Professor Lanas joined the faculty at University of Zaragoza in 1992.
Among other associations he is member and International Fellow of the American Gastroenterological Association, member of the General Assembly of the United European Gastroenterology Federation and the Spanish Association of Gastroenterology (AEG). He was president of the AEG for 4 years and now is the President of the AEG Foundation.
Dr. Lanas is actively involved in both clinical and basic investigation re
Paola Patrignani was graduated at the Faculty of Biological Sciences, “La Sapienza” University of Rome (Italy). Then, she followed a doctoral training in Pharmacology, at Catholic University of Rome, Italy. She worked for 2 years as Postdoctoral Research Fellow at Le Centre Hospitalier of Laval University (Quebec, Canada) and at the Department of Pharmacology of Merck Frosst (Kirkland, Quebec, Canada). She continued her academic career at “G. d’ Annunzio” University, School of Medicine, Chieti, Italy, where she is currently Professor of Pharmacology and Head of the Research Unit of Pharmacology and Pharmacodynamics of eicosanoids at the Center of Excellence on Aging (CeSI). In 2009 she was Guest professor of Pharmacology at Goethe-Universität Frankfurt am Main (Germany). She is a member of the Italian Society of Pharmacology and she received the Upjohn Award (1981) and the “Henry Christian” Award (1991). In 2013, she received a special prize awarded by the Committee for the Promotion of Female Entrepreneurship of Abruzzo Region (Italy).
Her scientific activity is documented by 150 peer-reviewed publications in international journals ranked in the Journal Citation Reports, and 21 chapters in national-international books. Her cumulative citation index is 6797: the h index is 42.
Short statements of expertise:
Carlo Patrono, MD, is Adjunct Professor of Pharmacology at the Catholic University School of Medicine in Rome, Italy and at the Perelman School of Medicine of the University of Pennsylvania in Philadelphia, USA. Dr. Patrono trained as a Postdoctoral Fellow in New York with the late Solomon Berson and Nobel Laureate Rosalyn Yalow.
Prof. Patrono’s main research interest is in the study of platelet activation and inhibition in atherothrombosis and colorectal cancer.
His research has characterized the human pharmacology of aspirin as an inhibitor of platelet COX-1 and provided the basis for the development of low-dose aspirin as an antithrombotic agent. During the past decade Prof. Patrono contributed to characterizing the human pharmacology of COX-2 inhibitors and evaluating their cardiovascular effects in different clinical settings.
He serves on the editorial board of the American Heart Association’s Journals, Circulation and Arteriosclerosis, Thrombosis, and Vascular Biology, and is a Section Editor of the Journal of the American College of Cardiology.
He has been elected to membership in scientific societies, including the Association of American Physicians, the Royal College of Physicians, the European Society of Cardiology, the Academia Europaea and the Accademia Nazionale dei Lincei.
He has received the Alexander B. Gutman award from the Mount Sinai School of Medicine, the Distinguished Award in Neuroscience from the Louisiana State University, the 1998 International Aspirin® Award from Bayer AG, the 2007 John Vane Award from the William Harvey Research Institute of the University of London, the 2011 Outstanding Achievement Award of the Eicosanoid Research Foundation, the 2013 Grand Prix Scientifique of the Institut de France, and the 2013 Lifetime Achievement Award of the European Association for Clinical Pharmacology and Therapeutics.
Prof. Patrono has published over 200 research articles with an h index of 86.
Action Research Professor of Neurology, Director of the Stroke Prevention Research Unit, University of Oxford
Peter Rothwell is the Action Research Professor of Neurology in the Nuffield Department of Clinical Neuroscience, University of Oxford. He qualified in medicine at the University of Edinburgh in 1987 and after completing his early postgraduate clinical training he moved to Oxford as Clinical Lecturer in Neurology in 1996. He was awarded an MRC Senior Clinical Fellowship in 1999 and set up the Stroke Prevention Research Unit in 2000, which now employs over 40 research staff.
He was awarded Professor of Clinical Neurology in 2004 and was elected a fellow of the Academy of Medical Sciences in 2008, a National Institute of Health Research Senior Investigator in 2009 and a Wellcome Trust Senior Investigator in 2011. He has published over 400 scientific papers and several books. His research interests include primary and secondary prevention of stroke, the effects of blood pressure on the brain, and the risks and benefits of aspirin.
He is clinically active, working as a Consultant Neurologist for the Oxford University Hospitals Trust and contributing to clinical services for general neurology and stroke prevention. He has received several awards for other areas of his research, including the Inaugural British Medical Journal Award for Outstanding Contribution to Clinical Research (2009), the Foulkes Foundation Medal, Academy of Medical Sciences (2009), the World Stroke Organisation President’s Biennial Award for Outstanding Research (2010), a Wellcome Trust Senior Investigator Award (2011), the Kinmonth Medal, Royal College of Surgeons (2012), the Queen’s Anniversary Prize for Higher and Further Education (2013) and The Inaugural International Aspirin Foundation Senior Scientific Award (2014).
Prof. Dr. Karsten Schrör
Institut für Pharmakologie und Klinische Pharmakologie
Heinrich-Heine-Universität
Düsseldorf
Education:
1961 – 1967 Medicine, Universität Halle/Wittenberg
1967 – 1972 Pharmacology, Universität Halle/Wittenberg
External residencies:
Wellcome Research Laboratories (UK); Supervisor: Sir John R. Vane, Department of Physiology, Jefferson Medical College, Philadelphia (USA); Supervisor: Prof. A.M. Lefer, Visiting Professor Medical University of South Carolina at Charleston (USA) (Prof. P.V. Halushka), Visiting Professor Department of Internal Medicine, Division of Hematology, University of Texas Medical Center, Houston (USA) (Prof. K.K. Wu)
Positions held
1967 – 1978 Research Assistant, Departments of Pharmacology, Universities Halle/Wittenberg, Mainz, Köln
1979 – 1984 Assistant Professor, Department of Pharmacology, University Köln
1984 – 1986 Associate Professor, Department of Pharmacology, University Köln
1986 – 2010 Professor of Pharmacology and Chairman of the Department of Pharmacology and Clinical Pharmacology, Heinrich-Heine-University Düsseldorf
2003 – 2006 Chairman of the Board, Working Group of the Chairmen of Departments of Pharmacology, Clinical Pharmacology and Toxicology at German Speaking Universities
2005/2010 Chairman of the German Society for Pharmacology
2007 – 2010 President of the German Society for Experimental and Clinical Pharmacology & Toxicology (DGPT)
Since 2012 Chairman of the European Platelet Academy, member since 2007
1992 Member of the Deutsche Akademie der Naturforscher Leopoldina (National Academy of Sciences)
2012 Schmiedeberg-Lifetime-Achievement-Award of the Deutsche Gesellschaft für Experimentelle und Klinische Pharmakologie und Toxikologie for Excellence in Science
Hungarian Society for Experimental and Clinical Pharmacology (Honorary Member)
National Health Research Institutes, Taiwan (Scientific Advisory Board Member)
Service in Editorial Boards (selected)
1988 – 1992 Eicosanoids (Managing Editor)
1980 – 2000 Naunyn Schmiedeberg’s Archives of Pharmacology
1984 – 2002 European Journal of Pharmacology (Consultant Editor)
1984 – 2004 Journal of Cardiovascular Pharmacology
2002 – 2006 Thrombosis Haemostasis (Section Editor)
1999 – 2009 Circulation Research
Publications:
About 500 original publications, reviews and several books on physiological and pharmacological aspects of myocardial infarction, pharmacology of platelet function, blood coagulation, prostaglandins, cellular effects of coagulation factors (thrombin, Xa) and signal transduction in vascular smooth muscle cells. Pharmacology and Clinics of Aspirin
Farhat Din completed her medical degree at St Andrews and Manchester University prior to returning to Edinburgh to undertake surgical training. She completed her MD thesis in examining the molecular mechanisms underlying NSAID- mediated prevention of colorectal cancer. She was awarded a Cancer Research UK Clinician Scientist fellowship in 2010. Currently she integrates her clinical practice as a consultant colorectal surgeon with her translational research programme investigating the effects of aspirin and other chemopreventive agents on mTOR signalling in colorectal cancer.
Colorectal cancer is a major cause of cancer death worldwide necessitating new strategies of disease control. Understanding the cellular signalling that governs growth of cancer cells holds the key to developing agents which interfere with cancer proliferation. The mTOR signalling pathway plays a pivotal role in controlling cell survival and regulation of cell metabolism and energy balance. Dysregulation of the mTOR signalling axis is implicated in the development of several cancers including colorectal cancer, supporting mTOR signalling as a promising target for chemoprevention. Our research focuses on colorectal cancer prevention by investigating the molecular mechanisms of the anti-tumour effects of chemopreventive agents such as aspirin on mTOR signalling to identify druggable targets in a pathway medicine approach.
http://www.nutshell-videos.ed.ac.uk/farhat-din-bowel-cancer-prevention/
Professor Eccles is Director of the Common Cold Centre at Cardiff University, Wales UK. He is an expert on the symptoms of common cold and flu and medicines used to treat colds and flu. He has spent his career at Cardiff University and he established the Common Cold Centre in Cardiff in 1988, a Clinical Research Organisation that conducts scientific and clinical research on treatments for cough, colds and flu. His recent research has studied the effects of chilling on the onset of common cold symptoms and the effects of placebo treatments. He has special interests in studying nasal congestion and cough, and has published many scientific papers on these topics He is the author of some 250 publications and has contributed to many medical textbooks.
I am based at the UK Medical Research Council Clinical Trials Unit at University College London where I jointly lead the Cancer Group; and have a clinical consultant post at the Brighton and Sussex University Hospital.
I have a particular interest in gastro-oesophageal malignancy and have co-ordinated a series of trials and associated translational studies, and have led the investigation of the use of transdermal oestrogen in the treatment of prostate cancer.
I am the Chief Investigator of an international trial (Add-Aspirin) designed to assess the effect of aspirin as an additional adjuvant agent in several common solid tumours.
Sign up to be part of the aspirin community and be the first to receive latest information.
Have something to say about aspirin?
Adjunct Associate Professor DUKE-NUS Graduate Medical School,
Consultant Oncologist Curie Oncology Singapore,
Visiting Consultant National Cancer Centre Singapore.
Medical Oncology
In the past 3 years, I have received consultant fees from Tessa Therapeutics, Aslan Pharmaceuticals, Novartis, and AstraZeneca.
I received grant support for investigator-initiated research from:
I hold shares in: Roche, BMS, AstraZeneca, Incyte, Teva Pharmaceuticals, Trillium Therapeutics, Compugen, Arrowhead pharmaceuticals, Emergex, QuantumDx and Halozyme Therapeutics
I received consultant and speakers fees from Amgen, AstraZeneca, Bayer, Lilly and Sanofi.
Junbo Ge
Ge Junbo, male, was born in Wulian, Shandong province on Nov. 8, 1962. He is the member of Chinese Academy of Sciences, professor and doctoral supervisor. He received his doctor’s degree of Medicine from German Mayence University in 1993 and now works as the director for Shanghai Institute of Cardiovascular Disease and the Center for Stem Cells and Tissue Engineering, Fudan University. He is also the designate chairman of the Cardiovascular Disease Branch of Chinese Medical Association, council member of the Cardiovascular Angiography and Interventions Association, international consultant of the American Heart Association. In Dec. 2013, he was appointed as the vice president of Tongji University.
Prof. Ge has been engaged in clinical and scientific research work of cardiovascular disease since 1987, and his research area covers the pathogenesis of coronary heart disease, early diagnosis and treatment plan optimization.
AACR Honors Dr. Andrew T. Chan With 2019 AACR-Waun Ki Hong Award
Click here to find the press release.
I received consultant Bayer and Pfizer, Inc.
I received grant support for investigator-initiated research from:
Professor of Medicine, Harvard Medical School; Chief Division of Aging, Brigham and Women’s Hospital; Director of Preventive Cardiology and Director of Massachusetts Veterans Epidemiology Research and Information Center (MAVERIC), VA Boston Healthcare System.
Discipline: Cardiology and Epidemiology
I received consultant and speaker fees Bayer.
I received grant support as a principal investigator or co-investigator for research from the VA, DOD, NIH, Merck and Kowa.
Peter M. Rothwell PhD, MD, FRCP, FMedSci
I received consultant and speakers fees from Acticor Biotech, Amgen, Bayer, GlaxoSmithKline, Tremeau, Zambon.
I received grant support for investigator-initiated research from:
Have something to say about aspirin?
We would like to hear from you and have a chat, and maybe feature you on our podcast. Please fill in the form below and we will contact you with further information.